Drug intelligence / Profile preview

SO-004D

Development stage: Preclinical
Lead developer: SOICUM
Modality: Small Molecules

Overview

SO-004D is a preclinical-stage small molecule new chemical entity (NCE) being developed by Socium (SOICUM) in collaboration with Nanjing Medical University. It is a new-compound derivative designed to enhance the efficacy of immuno-oncology (IO) agents. The drug is intended for the treatment of various cancers where IO therapies are indicated. While the specific molecular target has not been publicly disclosed, the program aims to improve clinical outcomes in IO-applicable malignancies by potentially modulating the tumor microenvironment or immune response.

Beyond the preview

Go deeper on SO-004D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-004D.

Explore the full profile